Vivo Bio Tech chairman and AGM
NSE: VIVOBIOTBSE: 511509Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 27 Oct 2026. Previous close ₹12.89.
27 Oct: open ₹12.58, high ₹14.99, low ₹12.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹31 Cr3,302nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.34
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −3.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹0.60 crore of one-off items, the largest of them in the quarter to Mar 2026.
- −2.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 5.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.72
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 24,29880.9% delivered
Vivo Bio Tech's chairperson is PRIYA RAJENDER GODA, as filed for the quarter to Sep 2026. Its latest annual general meeting was on 30 Sep 2026.
Vivo Bio Tech board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonPRIYA RAJENDER GODA
- Company Secretary and Compliance OfficerBhavish Vijayvargiya
6 directors2 independent3 executive1 non-executive
- SRI KALYAN KOMPELLAExecutive · joined Nov 2021 · 2 listed boards · 3 committee seats
- SANKARANARAYANAN ALANGUDIExecutive · joined Jan 2022 · 1 listed board
- KALYAN RAM MANGIPUDIExecutive · joined Nov 2009 · 1 listed board · 2 committee seats
- PRIYA RAJENDER GODA · ChairpersonIndependent · joined Jun 2025 · reappointed Jun 2025 · 15 months as independent · 2 listed boards · 2 as independent · 3 committee seats, 2 as chair
- SATYANARAYANA VEDULANon-executive · joined Jun 2025 · 2 listed boards
- SHYAM SUNDER TIPPARAJUIndependent · joined Aug 2023 · reappointed Aug 2023 · 37 months as independent · 2 listed boards · 2 as independent · 2 committee seats
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
2 directors who left
- KUNDA KALPANA, left 29 Jun 2025: Tenure Completion
- SHIVANAND NAYAK KAROPADI, left 6 May 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 22 Aug 20266 of 6 present2 independent
- 13 Jul 20266 of 6 present2 independent · 18 days in between
- 24 Jun 20266 of 6 present2 independent · 24 days in between
- 30 May 20266 of 6 present2 independent
Audit Committee
Chair PRIYA RAJENDER GODA
SHYAM SUNDER TIPPARAJU, KALYAN RAM MANGIPUDI
- 22 Aug 20263 of 3 present2 independent · 39 days in between
- 13 Jul 20263 of 3 present2 independent · 43 days in between
- 30 May 20263 of 3 present2 independent
Nomination and remuneration committee
Chair SHYAM SUNDER TIPPARAJU
PRIYA RAJENDER GODA, SATYANARAYANA VEDULA
- 22 Aug 20263 of 3 present2 independent · 58 days in between
- 24 Jun 20263 of 3 present2 independent · 24 days in between
- 30 May 20263 of 3 present2 independent
Stakeholders Relationship Committee
Chair PRIYA RAJENDER GODA
KALYAN RAM MANGIPUDI, SRI KALYAN KOMPELLA
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- P MURALI & CO.,Peer-review certificate valid to Nov 2028
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Vivo Bio Tech AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.
Annual general meeting, 30 Sep 2026
21,413 shareholders on the register on 23 Sep 2026; present: 1 promoter and 66 others; votes counted by VINAY BABU GADE / NOT APPLICABLE.The company's voting result
To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, the Report of the Auditors' thereon and the Report of the Board of DirectorsMoreLess
Ordinary99.68% for0.32% againstAgainst: promoters 0.00% · other public 0.36%
Turnout: all 48.12% · promoters 24.03% · other public 55.12%
- To appoint a Director in place of Mr. Kalyan Ram Mangipudi (DIN: 02012580) who retires by rotation, and being eligible, offers himself for re-appointmentOrdinaryPromoters have an interest in it99.68% for0.32% against
Against: promoters 0.00% · other public 0.36%
Turnout: all 48.12% · promoters 24.03% · other public 55.12%
- Re-appointment of Mr. Sri Kalyan Kompella (DIN: 03137506) as the Whole-time Director of the CompanyOrdinary99.68% for0.32% against
Against: promoters 0.00% · other public 0.36%
Turnout: all 48.12% · promoters 24.03% · other public 55.12%
- Re-appointment of Dr. Sankaranarayanan Alangudi (DIN: 02703392) as the Whole-time Director of the CompanySpecial99.68% for0.32% against
Against: promoters 0.00% · other public 0.36%
Turnout: all 48.12% · promoters 24.03% · other public 55.12%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.